Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study

Ticagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso‐occlusion crisis (VOC) in sickle cell disease (SCD). The HESTIA2 study (NCT02482298) randomised 87 adults with SCD (aged 18–30 years) 1:1:1 to twice‐d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanter, Julie, Abboud, Miguel R., Kaya, Banu, Nduba, Videlis, Amilon, Carl, Gottfridsson, Christer, Rensfeldt, Martin, Leonsson‐Zachrisson, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Red Cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587797/
https://www.ncbi.nlm.nih.gov/pubmed/30443999
http://dx.doi.org/10.1111/bjh.15646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587797/
https://www.ncbi.nlm.nih.gov/pubmed/30443999
http://dx.doi.org/10.1111/bjh.15646

Ejemplares similares